Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Operating Income (2016 - 2025)

Historic Operating Income for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$52.4 million.

  • Regenxbio's Operating Income rose 1557.23% to -$52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.9 million, marking a year-over-year increase of 3698.98%. This contributed to the annual value of -$233.3 million for FY2024, which is 1297.22% up from last year.
  • Latest data reveals that Regenxbio reported Operating Income of -$52.4 million as of Q3 2025, which was up 1557.23% from -$63.3 million recorded in Q2 2025.
  • Regenxbio's Operating Income's 5-year high stood at $313.6 million during Q4 2021, with a 5-year trough of -$73.1 million in Q2 2023.
  • Its 5-year average for Operating Income is -$37.3 million, with a median of -$62.1 million in 2024.
  • The largest annual percentage gain for Regenxbio's Operating Income in the last 5 years was 68451.1% (2021), contrasted with its biggest fall of 51106.73% (2021).
  • Quarter analysis of 5 years shows Regenxbio's Operating Income stood at $313.6 million in 2021, then crashed by 118.42% to -$57.8 million in 2022, then decreased by 10.61% to -$63.9 million in 2023, then grew by 19.62% to -$51.4 million in 2024, then dropped by 2.03% to -$52.4 million in 2025.
  • Its Operating Income stands at -$52.4 million for Q3 2025, versus -$63.3 million for Q2 2025 and $12.1 million for Q1 2025.